We explored the relationship between the IFN-γ -associated gene scoring model and various clinicopathological factors, and found that patients with advanced tumor grade, Astrocytoma, wild-type IDH1, 1P/19Q non-co-deletion, and wild-type ATRX had significantly higher risk scores (p < 0.05, Figures 4A–E). This evidence concerns the gene ATRX and astrocytoma (excluding glioblastoma).